Zacks Investment Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Zacks Investment Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,210	Closed	-$118K	–	664
2017 Q3	$118K	Buy	+2,210	New	+$131K	﹤0.01%	563
2016 Q4	–	Sell	-3,360	Closed	-$209K	–	764
2016 Q3	$209K	Buy	3,360 +1,024	+44%	+$72.4K	0.01%	588
2016 Q2	$132K	Hold	2,336	–	–	﹤0.01%	602
2016 Q1	$150K	Buy	+2,336	New	+$189K	﹤0.01%	571

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Zacks Investment Management's KDNY Position: Q4 2017 in Review

Zacks Investment Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2017, closing a stake of 2,210 shares — an estimated $118K sold.

Zacks Investment Management first reported a position in KDNY in Q1 2016 and held it in 4 quarters. The position peaked at $209K in Q3 2016. 94 funds tracked by Wall St. Rank hold KDNY as of Q4 2017.

Zacks Investment Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Zacks Investment Management sold 2,210 Chinook Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $118K.
Zacks Investment Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 4 quarters.
Zacks Investment Management's Chinook Therapeutics, Inc. Common Stock position peaked at $209K in Q3 2016.
94 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Zacks Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.